

## CabinetBecker.4006.ST25.txt SEQUENCE LISTING

```
AP Cells, Inc.
Lamparski, Henry
<110>
       Ruegg, Curtis
       Le-Pecq, Jean-Bernard
Hsu, Di-Hwei
       Yao, Jenq-Yuan
       Methods of Producing Membrane Vesicles
<120>
       260/058 702015.6
<130>
       us 09/780,748
<140>
        2001-02-09
<141>
       us 09/561,205
<150>
       2000-04-27
 <151>
 <160>
       PatentIn version 3.2
 <170>
 <210>
        10
 <211>
 <212>
        PRT
         Hepatitis B
 <213>
 <220>
         peptide
  <221>
         derived from HLA-2 restricted core antigen
         (1)..(10)
  <222>
  <223>
  <400> 1
  Phe Leu Pro Ser Asp Cys Phe Pro Ser Val
         2
9
  <210>
  <211>
          PRT
  <212>
          Homo sapiens
   <213>
   <220>
          peptide
   <221>
          (1)..(9)
   <222>
          Derived from MAGE melanoma antigen
   <223>
   <400> 2
   Glu Val Asp Pro Ile Gly His Leu Tyr
1
           3
   <210>
           10
    <211>
    <212>
           PRT
          Homo sapiens
    <213>
```

## CabinetBecker.4006.ST25.txt

```
<220>
<221> peptide <222> (1)..(10)
<223> Derived from MART-1 melanoma antigen
<400> 3
Glu Leu Ala Gly Ile Gly Ile Leu Thr Val
        4
<210>
       8
<211>
<212> PRT
<213> Homo sapiens
<220>
<221>
        peptide
       (1)..(8)
 <222>
       Derived from ovalbumin residues 257-269
<400>
 Ser Ile Ile Asn Phe Glu Lys Leu
1 5
 <210>
         5
        9
 <211>
 <212> PRT
 <213> Artificial peptide
 <220>
        isoleucine to cysteine substitution
 <223>
  <220>
         (1)..(9)
Derived from MAGE 3A1 peptide by substitution of cytosine for
         peptide
  <221>
  <222>
  <223>
         isoleucine
  <400> 5
  Glu Val Asp Pro Cys Gly His Leu Tyr
1
```

## SEQUENCE LISTING 0> AP Cells, Inc. Lamparski, Henry Ruegg, Curtis Le-Pecq, Jean-Bernard Hsu, Di-Hwei Yao, Jenq-Yuan <120> Methods of Producing Membrane Vesicles <130> 260/058 702015.6 <140> US 09/780,748 <141> 2001-02-09 <150> US 09/561,205 <151> 2000-04-27 <160> 5 <170> PatentIn version 3.2 <210> 1 <211> 10 <212> PRT <213> Hepatitis B <220> <221> peptide <222> (1)..(10) <223> derived from HLA-2 restricted core antigen <400> 1 Phe Leu Pro Ser Asp Cys Phe Pro Ser Val 5 <210> 2 <211> 9 <212> PRT <213> Homo sapiens <220> <221> peptide <222> (1)..(9) <223> Derived from MAGE melanoma antigen <400> 2 Glu Val Asp Pro Ile Gly His Leu Tyr

```
<211> 10
<212> PRT
<213> Homo sapiens
<220>
<221> peptide
<222> (1)..(10)
<223> Derived from MART-1 melanoma antigen
<400> 3
Glu Leu Ala Gly Ile Gly Ile Leu Thr Val
     5
<210> 4
<211> 8
<212> PRT
<213> Homo sapiens
<220>
<221> peptide
<222> (1)..(8)
<223> Derived from ovalbumin residues 257-269
<400> 4
Ser lle lle Asn Phe Glu Lys Leu
<210> 5
<211> 9
<212> PRT
<213> Artificial peptide
<220>
<223> isoleucine to cysteine substitution
<220>
<221> peptide
<222> (1)..(9)
<223> Derived from MAGE 3A1 peptide by substitution of cytosine for
    isoleucine
<400> 5
Glu Val Asp Pro Cys Gly His Leu Tyr
```